Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Analytik Jena to Develop Products for Sepsis Diagnostics

Published: Tuesday, May 07, 2013
Last Updated: Tuesday, May 07, 2013
Bookmark and Share
Cooperation to continue with the scientific centers for sepsis research in Jena.

Analytik Jena has acquired all of the assets of the insolvent company SIRS-Lab GmbH as part of an asset deal. A contract covering the deal was signed by the Jena-based instrument manufacturer and the insolvency administrator LEONHARDT.

SIRS-Lab, a company that develops molecular diagnostics methods and testing systems for life-threatening infections like sepsis, had filed for insolvency in December 2012.

Analytik Jena AG, which as part of the acquisition will also take on the entire range of product expertise, including more than 50 patents and 10 employees at the Jena site, will for the first time be entering the worldwide growth market of sepsis diagnostics, continuing the intensive development work and the expertise of SIRS-Lab in this field.

"In recent years, SIRS-Lab has built up considerable competence in the field of sepsis analytics and has achieved initial successes. The results from a first application study are highly promising. The aim is to identify life-threatening infections quickly and early. In particular, the region around Jena with the University Hospital and various research institutions offers excellent conditions to allow us to be able to serve this large market with products in the future," says Klaus Berka, CEO of Analytik Jena AG.

SIRS-Lab was founded in 2000 as a spin-off of the Friedrich Schiller University at the Jena Sepsis Competence Center by a high-caliber team of scientists of international renown with the aim of combating the high mortality rate associated with sepsis (blood poisoning).

Among the founders were such renowned scientists as Prof. Dr. Konrad Reinhart, Director of the Clinic for Anesthesiology and Intensive Medicine, Prof. Dr. Eberhard Straube, former Director of the Institute for Medical Microbiology at the University of Jena, and Prof. Dr. Hanspeter Saluz, Head of the Cell and Molecular Biology department at the Hans-Knöll Institute in Jena.

With the product LOOXSTER®, the company developed a patented technology for concentrating bacterial and fungal DNA in diagnostic samples. This product has been used in VYOO®, the CE-certified product for sepsis diagnostics.

SIRS-Lab was also developing an innovative gene expression product (SIQNATURE®) to indicate the body's immune response to an infection.

A related test developed by SIRS-Lab is almost ready for the market. All SIRS-Lab developments are designed to enable improved and faster diagnostics on patients with systemic infections.

"I am delighted that, in the form of Analytik Jena, an investor has been found who will continue the valuable work that has been carried out in recent years in the field of the diagnosis of life-threatening infections, continuing the fight against sepsis," says Prof. Konrad Reinhart, Director of the Clinic for Anesthesiology and Intensive Therapy (KAI) at the University Hospital of Jena.

Analytik Jena, which is already profiting from revenue in the public healthcare sector in the field of life science, has set out plans to focus more strongly on routine diagnostics and to work more closely with hospital and clinical partners in the process.

SIRS-Lab was a member of the German Sepsis Society and collaborated with many internationally renowned partners, including the University Hospital of the Friedrich Schiller University Jena, which only received the green light from an international jury of experts to develop an integrated research and treatment center for sepsis and related illnesses in January 2010.

"We also see our commitment in a regional context," explains Berka. Accordingly, one of the main concerns is to keep important expertise and research and development capacities at the site.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Analytik Jena Opens Swiss Branch Office in Reinach
Direct service and supply for Analytical Instrumentation customers in the Swiss market.
Thursday, October 29, 2015
Analytik Jena AG Completes Merger of CyBio AG
Merger became effective upon entry into the commercial register of Analytik Jena AG.
Thursday, July 10, 2014
Analytik Jena CEO Klaus Berka Becomes an Advisor of the Fraunhofer IZI
Klaus Berka to advise the institute's management and the Executive Board of the Fraunhofer Gesellschaft.
Saturday, May 17, 2014
Analytik Jena Appoints New MD at Japanese Subsidiary
Dr. Marco Tilgner has been appointed new managing director of the Japanese subsidiary AJ Japan as of January 1, 2014.
Monday, December 09, 2013
Analytik Jena Establishes Subsidiary in Thailand
New company to bolster Analytik Jena’s activities in the Southeast Asian market.
Tuesday, May 07, 2013
Analytik Jena to Develop Products for Sepsis Diagnostics
Integration of a core team of former employees in the Life Science business unit. Cooperation to continue with the scientific centers for sepsis research in Jena.
Tuesday, May 07, 2013
Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%
The Jena-based manufacturer of analytical instrumentation technology, life science instruments and optoelectronics has thus integrated another subsidiary further into the Group.
Monday, April 23, 2012
Scientific News
New Tool Could Change How Infectious Diseases Are Diagnosed
Scientists at the University of Utah School of Medicine, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer that dramatically improves the accuracy and speed of pathogen detection.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!